Core Viewpoint - The report from CITIC Construction Investment maintains a "Buy" rating for MicroTech Medical-B (02235), forecasting significant revenue and profit growth from 2025 to 2027, driven by the rapid expansion of Continuous Glucose Monitoring (CGM) products both domestically and internationally [1][2] Group 1: Financial Projections - Revenue projections for MicroTech Medical-B are expected to reach 5.31 billion, 7.89 billion, and 10.66 billion yuan for 2025, 2026, and 2027, representing year-on-year growth rates of 53.78%, 48.53%, and 35.00% respectively [1] - The company's net profit attributable to shareholders is forecasted to be 0.03 billion, 0.43 billion, and 0.93 billion yuan for the same years, with staggering growth rates of 103.99%, 1618.91%, and 115.63% respectively [1] - The price-to-sales (PS) ratios for 2025, 2026, and 2027 are projected to be 6.24, 4.20, and 3.11 times respectively based on the closing price on October 13, 2025 [1] Group 2: Market Dynamics - The company experienced significant growth in the first half of 2025, with a substantial reduction in losses, primarily due to the rapid market penetration of CGM products [1] - The domestic market is expected to continue its growth trend through a combination of online e-commerce and offline hospital sales, while the second-generation CGM has entered multiple European countries' healthcare systems, indicating a large potential for market share expansion [1] - The approval of the core product, Equil patch insulin pump, for use in children and adolescents aged 3-17 years is anticipated to contribute to structural growth in the second half of the year [1] Group 3: Long-term Outlook - In the short term, the company is expected to maintain high revenue growth driven by the ongoing expansion of CGM products in both domestic and international markets, with a potential to achieve breakeven for the year [2] - In the medium to long term, the company holds a unique position as the only domestic firm with both patch insulin pumps and non-calibrated CGM products, providing a significant product portfolio advantage [2] - The upcoming launch of second-generation insulin pumps, artificial pancreas systems, and advancements in AI are expected to solidify the company's global leadership in diabetes management and open up long-term growth opportunities [2]